My GLP-1 changed how I feel about alcohol. Is that real?

The glass is still full.

You poured the wine you usually look forward to. Maybe you took a few sips. Maybe you forgot about it altogether.

You are taking a GLP-1 medicine, and something you did not expect has changed: you just do not want the drink the way you used to.

Could the medicine be part of the reason?

Researchers are asking the same question.

Early human studies suggest that semaglutide and other medicines that act on the GLP-1 pathway may change alcohol craving or drinking in some people. But this is where the distinction matters: interesting is not the same as proven.

GLP-1 medicines are not currently approved as treatments for alcohol use disorder, and the studies so far have not all produced the same result.

What have researchers actually found?

One of the earlier studies tested exenatide, another GLP-1 medicine, in adults with alcohol use disorder. It did not reduce heavy-drinking days more than placebo across the whole study group.

Then came semaglutide.

A small 2025 trial found that people receiving semaglutide reported less alcohol craving and improvements in some measures of drinking.

In 2026, another study followed 108 adults who had both alcohol use disorder and obesity. People receiving semaglutide had fewer heavy-drinking days than those receiving placebo.

Researchers have also studied oral semaglutide—the pill form. That small study found improvements in some drinking measures, including heavy-drinking days, but not every outcome improved.

That is why the answer today is not:

GLP-1 medicines treat alcohol use disorder.

It is:

Something interesting may be happening, and researchers are trying to understand exactly what it is.

A quick word about placebo

You will see that word throughout medical research.

A placebo is a treatment made to resemble the treatment being studied but without the active medicine.

In an injection study, that may mean a matching injection—not necessarily the “sugar pill” people often picture.

Researchers compare the groups to help determine how much of the difference is actually attributable to the medicine.

Then there is brenipatide

Brenipatide is not semaglutide.

It is an experimental medicine designed to act on two hormone pathways: GIP and GLP-1.

It is now being studied specifically for alcohol use disorder in two large Phase 3 trials called RENEW-ALC-1 and RENEW-ALC-2.

Together, the trials are expected to enroll about 2,200 adults and follow drinking patterns and safety for roughly a year.

There are no results yet.

That sentence matters.

A positive finding with semaglutide does not prove that brenipatide will work. And results from one GLP-1 medicine cannot automatically be applied to every medicine in the class.

Why researchers are paying attention

Because both primary-care and specialist clinicians are increasingly familiar with GLP-1 medicines, Dr. Henry Kranzler expects that, if a GLP-1–based medicine is eventually shown to be effective and receives regulatory approval for alcohol use disorder, that familiarity could substantially broaden the prescriber base. He also expects addiction-treatment clinicians to embrace the drug class, given its lack of known abuse potential.

But that is a future possibility.

It is not where the evidence stands today.

For now, evidence of efficacy remains limited. Until there are compelling Phase 3 results, these medicines should not be presented to patients as proven treatments for alcohol use disorder.

Early findings should not replace treatments that already have evidence behind them.

Why this belongs in HEART RESERVE

Because alcohol does not live in one box.

It can affect blood pressure.

Heart rhythm.

Sleep.

Weight.

Liver health.

And the decisions you make about your health rarely stay inside the specialty where they began.

That is part of the HEART RESERVE idea: your body keeps one story, even when medicine divides it into separate appointments.

There is another distinction worth protecting.

A medicine reducing alcohol intake is one question.

A medicine preventing heart attacks, strokes, or other cardiovascular events is another.

We cannot assume the second because we are beginning to see evidence for the first.

The RENEW-ALC studies are not cardiovascular-outcomes trials.

What should you do if you notice this?

Do not dismiss it.

Bring it into the appointment.

Tell your prescriber what you have noticed—not only the number on the scale, but whether your appetite, drinking, cravings, sleep, strength, or usual routines have changed.

You can simply say:

“Since starting this medicine, my interest in alcohol has changed. Is that something we should talk about?”

That one observation may open a much bigger conversation about your health.

And if drinking has become difficult to control or is causing harm, you do not need to wait for the GLP-1 research to catch up. Effective treatments for alcohol use disorder already exist.

If you drink heavily or have experienced alcohol withdrawal before, do not suddenly stop drinking without medical guidance. Alcohol withdrawal can be dangerous.

The research is still evolving.

The glass sitting unfinished may be a clue. We are still learning what it means.

HEART RESERVE provides educational information and does not replace individualized medical care. Do not start, stop, or change a prescription medicine without discussing it with your clinician.